Author Archives: admin


Stem Cell Clinic > Articles by: admin

Quality Smart Solutions Launches GRAS Experts to Protect Against Food Safety Risks

By Global News Feed

TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- In light of McDonald’s recent recall of Quarter Pounders due to E. coli contamination, the need for stringent oversight on food ingredients has never been more critical. Quality Smart Solutions has launched GRAS Experts, a new division aimed at tackling ingredient safety concerns and helping businesses stay ahead of regulatory changes and avoiding recalls.

See the article here:
Quality Smart Solutions Launches GRAS Experts to Protect Against Food Safety Risks

Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv

By Global News Feed

Oslo, October 25, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the results from Phase II FOCUS trial (NCT05075122) have been published online on the preprint platform medRxiv.

Read the original:
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

By Global News Feed

LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the closing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the “Offering”) at a public offering price of $3.50 per share, for total gross proceeds of $63.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. All of the shares in the Offering were sold by ProQR.

See original here:
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that the Board of Directors of Firefly granted 557,885 restricted shares (the “Shares”) as an inducement grant to David Johnson, the Company's Executive Chairman, pursuant to that certain Employment Agreement (the “Agreement”), by and between the Company and Mr. Johnson. The Shares were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the Agreement and the Company’s 2024 Long-Term Incentive Plan.

Read more from the original source:
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Helio Genomics and Halub Medical Co. Announce Strategic Partnership to Commercialize HelioLiver Dx in The Gulf Cooperation Council and Middle East

By Global News Feed

IRVINE, Calif., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven biotechnology company specializing in diagnostics technology and test development for cancer detection, today announced the strategic partnership, in commercializing HelioLiver Dx in Saudi Arabia, with Halub Medical Co., a healthcare company for Saudi Arabia, GCC and Middle East. The test is expected to be commercially available in Saudi Arabia and The Gulf Cooperation Council (GCC) in Q1 2025, with the following 12-month revenue for Helio expected to exceed $10 million dollars.

See original here:
Helio Genomics and Halub Medical Co. Announce Strategic Partnership to Commercialize HelioLiver Dx in The Gulf Cooperation Council and Middle East

Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

By Global News Feed

WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today provided additional guidance on the first clinical product of the company’s proprietary ExacTcell™ technology, TVGN 489, designed to treat SARS-CoV-2 infections in immunocompromised oncology patients, and a subgroup of patients with post-acute sequelae of SARS-CoV-2 (PASC).

Here is the original post:
Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic…

By Global News Feed

HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company’s Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD.

See the original post:
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic...

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

By Global News Feed

WALTHAM, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 3 VALIANT study were presented as an oral presentation during the High-Impact Clinical Trials session at the American Society of Nephrology (ASN) Kidney Week. The results highlighted the strength of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, debilitating kidney diseases.

More:
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

→←